Budesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Quality, real-world comparative effectiveness (CE) studies of asthma and chronic obstructive pulmonary disease therapy efficacy are scarce. We identified and evaluated peer-reviewed CE and appropriate-use evaluations of budesonide/formoterol combination (BFC) maintenance therapy. Materials & methods: Analyses were limited to retrospective, real-world utilization studies of BFC delivered by pressurized metered-dose inhalers. Results: In a CE study of BFC versus fluticasone/salmeterol combinations (FSC) in asthma, BFC users had fewer total exacerbations. In appropriate-use studies of asthma treatment, BFC patients were consistently more likely to meet treatment escalation recommendations. BFC comparisons with FSC or tiotropium for chronic obstructive pulmonary disease found differences in exacerbation rates and rescue inhaler use. Conclusion: We found available, good quality BFC CE and appropriate-use articles; however, all had limitations.
Supplementary Material
File (suppl_data.zip)
- Download
- 116.65 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
National Asthma Education Prevention Panel. Expert Panel Report 3: guidelines for the diagnosis and management of asthma summary report 2007. J. Allergy Clin. Immunol. 120, S94–S138 (2007).
2.
Su KC, Tsai CC, Kuo LC, Kuo SH, Perng DW. Budesonide/formoterol combination as a maintenance and rescue therapy: physicians' perspectives. J. Asthma 46(7), 647–651 (2009).
3.
Johansson G, Stallberg B, Tornling G et al. Asthma treatment preference study: a conjoint analysis of preferred drug treatments. Chest 125(3), 916–923 (2004).
4.
Celli BR. Update on the management of COPD. Chest 133(6), 1451–1462 (2008).
5.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 Report) (2018). https://goldcopd.org/gold-reports
6.
Corren J, Korenblat PE, Miller CJ, O'brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin. Ther. 29(5), 823–843 (2007).
7.
Noonan M, Rosenwasser LJ, Martin P, O'brien CD, O'dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 66(17), 2235–2254 (2006).
8.
Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21(1), 74–81 (2003).
9.
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22(6), 912–919 (2003).
10.
Tashkin DP, Rennard SI, Martin P et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68(14), 1975–2000 (2008).
11.
Rennard SI, Tashkin DP, Mcelhattan J et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69(5), 549–565 (2009).
12.
Ferguson GT, Tashkin DP, Skarby T et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir. Med. 132, 31–41 (2017).
13.
Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 106(2), 257–268 (2012).
14.
Grembiale RD, Pelaia G, Naty S, Vatrella A, Tranfa CM, Marsico SA. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm. Pharmacol. Ther. 15(5), 463–466 (2002).
15.
Ismaila A, Corriveau D, Vaillancourt J et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr. Med. Res. Opin. 30(7), 1427–1436 (2014).
16.
Brixner DI, Lenhart G, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. Curr. Med. Res. Opin. 23(11), 2887–2895 (2007).
17.
Schoening SK. Issues and challenges for managed care in the treatment of asthma and chronic obstructive pulmonary disease. Am. J. Manag. Care 10(Suppl. 5), S158–S163 (2004).
18.
Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas Medicaid patients with persistent asthma. J. Manag. Care Spec. Pharm. 21(12), 1124–1132 (2015).
19.
Vestbo J, Anderson JA, Calverley PM et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 64(11), 939–943 (2009).
20.
Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst. Rev. (12), CD004106 (2011).
21.
Tunceli O, Williams SA, Kern DM et al. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis. J. Allergy Clin. Immunol. Pract. 2(6), 719–726 (2014).
22.
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 10(5), 326–335 (2007).
• Provides a thoughtful assessment of the benefits and limitations of using real-world effectiveness data from observational studies that review effectiveness of therapies beyond clinical efficacy outcomes (traditionally done using randomized control trials).
23.
Berger ML, Martin BC, Husereau D et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 17(2), 143–156 (2014).
•• One of three core articles that are recommended reading for gaining a better understanding of real-world observational studies. To be an aid in decision making, study findings must be relevant as well as credible. This article highlights assessment of those qualities as well as fatal flaws that would exclude using an article.
24.
Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report–Part II. Value Health 12(8), 1053–1061 (2009).
•• One of three core articles that are recommended reading for gaining a better understanding of real-world observational studies. This article is one of a three-part series on using nonrandomized studies for comparative effectiveness research. The authors highlight key issues related to measurement of exposure and outcome that must be considered to minimize bias and confounding.
25.
Roche N, Reddel H, Martin R et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann. Am. Thorac. Soc. 11(Suppl. 2), S99–S104 (2014).
•• One of three core articles that are recommended reading for gaining a better understanding of real-world observational studies. Standards set forth by the Respiratory Effectiveness Group stressed three points to ensure quality of included studies for analysis: preparation of research, analyses and reporting, and discussion of results.
26.
Filion KB, Eberg M, Ernst P. Confounding by drug formulary restriction in pharmacoepidemiologic research. Pharmacoepidemiol. Drug Saf. 25(3), 278–286 (2016).
27.
Florentinus SR, Heerdink ER, Van Dijk L, Griens AM, Groenewegen PP, Leufkens HG. Is new drug prescribing in primary care specialist induced? BMC Health Serv. Res. 9, 6 (2009).
28.
Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am. J. Epidemiol. 144(12), 1161–1169 (1996).
29.
National Heart Lung and Blood Institute. National asthma education and prevention program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007 (2007). https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma
30.
Blanchette CM, Culler SD, Ershoff D, Gutierrez B. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma. Clin. Ther. 31(11), 2574–2583 (2009).
31.
Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr. Med. Res. Opin. 25(9), 2251–2258 (2009).
32.
Tunceli O, Kern DM, Williams SA, Pethick N, Suchower L, Ramachandran S. Initiation of inhaled corticosteroid and long-acting b2-adrenergic agonist (ICS/LABA) in asthma. Am. J. Pharm. Ben. 6(3), e70–e78 (2014).
33.
Global Initiative for Asthma. Global strategy for asthma management and prevention (2019). https://ginasthma.org/gina-reports/
34.
Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J. Med. Econ. 14(6), 769–776 (2011).
35.
Streiner DL, Norman GR. The pros and cons of propensity scores. Chest 142(6), 1380–1382 (2012).
• This article is a timely reminder that although propensity scores can be a powerful tool, they are a tool that must be used thoughtfully, and optimally will also include sensitivity analyses.
36.
Mapel D, Roberts MH, Blanchette CM, Petersen H, Ramachandran S. Effectiveness of inhaled combined corticosteroid/long-acting bronchodilator treatment in reducing COPD exacerbations and short-acting bronchodilator use. J. Clin. Outcomes Manag. 20(2), 60–68 (2013).
37.
Kern DM, Davis J, Williams SA et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir. Res. 16, 52 (2015).
38.
Davis JR, Kern DM, Williams SA et al. Health care utilization and costs after initiating budesonide/formoterol combination or fluticasone/salmeterol combination among COPD patients new to ICS/LABA treatment. J. Manag. Care Spec. Pharm. 22(3), 293–304 (2016).
39.
Kern DM, Williams SA, Tunceli O et al. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 775–783 (2014).
40.
Trudo F, Kern DM, Davis JR et al. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2055–2066 (2015).
41.
Cates CJ, Schmidt S, Ferrer M, Sayer B, Waterson S. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cochrane Database Syst. Rev. (2018) (Epub ahead of print).
42.
Janjua S, Schmidt S, Ferrer M, Cates CJ. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database Syst. Rev. (2019) (Epub ahead of print).
43.
U.S. Food and Drug Administration. FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS) (2017). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes
44.
Mapel D, Laliberte F, Roberts MH et al. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 1825–1836 (2017).
45.
Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin. Ther. 32(7), 1320–1328 (2010).
46.
Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 3055–3064 (2017).
Information & Authors
Information
Published In
Pages: 231 - 251
PubMed: 31983228
Copyright
© 2020 Melissa H Roberts. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 30 October 2019
Accepted: 19 December 2019
Published online: 27 January 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Budesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0161
Export citation
Select the citation format you wish to export for this article or chapter.